162 related articles for article (PubMed ID: 26229408)
1. Boceprevir early-access for advanced-fibrosis/cirrhosis in Asia-Pacific hepatitis C virus genotype 1 non-responders/relapsers.
Sukeepaisarnjaroen W; Pham T; Tanwandee T; Nazareth S; Galhenage S; Mollison L; Totten L; Wigg A; Altus R; Colman A; Morales B; Mason S; Jones T; Leembruggen N; Fragomelli V; Sendall C; Guan R; Sutedja D; Tan SS; Dan YY; Lee YM; Luman W; Teo EK; Than YM; Piratvisuth T; Lim SG
World J Gastroenterol; 2015 Jul; 21(28):8660-9. PubMed ID: 26229408
[TBL] [Abstract][Full Text] [Related]
2. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C; Fontaine H; Dorival C; Zoulim F; Larrey D; Canva V; De Ledinghen V; Poynard T; Samuel D; Bourliere M; Alric L; Raabe JJ; Zarski JP; Marcellin P; Riachi G; Bernard PH; Loustaud-Ratti V; Chazouilleres O; Abergel A; Guyader D; Metivier S; Tran A; Di Martino V; Causse X; Dao T; Lucidarme D; Portal I; Cacoub P; Gournay J; Grando-Lemaire V; Hillon P; Attali P; Fontanges T; Rosa I; Petrov-Sanchez V; Barthe Y; Pawlotsky JM; Pol S; Carrat F; Bronowicki JP;
Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
[TBL] [Abstract][Full Text] [Related]
4. Chronic hepatitis C genotype 1 treatment roadmap for resource constrained settings.
Lim SG
World J Gastroenterol; 2015 Feb; 21(6):1972-81. PubMed ID: 25684966
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of boceprevir co-administration versus pegylated interferon-α2b and ribavirin only for patients with hepatitis C genotype 1 in Singapore.
Dan YY; Ferrante SA; Elbasha EH; Hsu TY
Antivir Ther; 2015; 20(2):209-16. PubMed ID: 25105844
[TBL] [Abstract][Full Text] [Related]
6. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
[TBL] [Abstract][Full Text] [Related]
7. Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy.
Hayashi K; Katano Y; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
Liver Int; 2011 Oct; 31(9):1359-65. PubMed ID: 21745312
[TBL] [Abstract][Full Text] [Related]
8. [Lead-in period and week 8 as predictive tools for response to boceprevir therapy: a retrospective study of Spanish real clinical practice].
Crespo J; Berenguer M; Pérez F; Fernández I; González O; Bárcena R; Buti M; López J; Calleja JL;
Gastroenterol Hepatol; 2015 Nov; 38(9):517-24. PubMed ID: 25976446
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis C in Asia: when East meets West.
Yu ML; Chuang WL
J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
[TBL] [Abstract][Full Text] [Related]
10. Future treatment of patients with HCV cirrhosis.
Bourlière M; Khaloun A; Wartelle-Bladou C; Oules V; Portal I; Benali S; Adhoute X; Castellani P
Liver Int; 2012 Feb; 32 Suppl 1():113-9. PubMed ID: 22212581
[TBL] [Abstract][Full Text] [Related]
11. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
Bailly F; Virlogeux V; Dufour C; Pradat P; Hézode C; Larrey D; Alric L; Samuel D; Bourlière M; Métivier S; Zarski JP; Fontaine H; Loustaud-Ratti V; Serfaty L; Bronowicki JP; Carrat F; Zoulim F;
Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
[TBL] [Abstract][Full Text] [Related]
12. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
Sperl J; Frankova S; Senkerikova R; Neroldova M; Hejda V; Volfova M; Merta D; Viklicky O; Spicak J; Jirsa M
World J Gastroenterol; 2015 May; 21(18):5496-504. PubMed ID: 25987772
[TBL] [Abstract][Full Text] [Related]
13. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
14. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
Coppola N; Pisaturo M; Sagnelli C; Sagnelli E; Angelillo IF
PLoS One; 2014; 9(4):e94542. PubMed ID: 24728219
[TBL] [Abstract][Full Text] [Related]
15. Factors that predict response of patients with hepatitis C virus infection to boceprevir.
Poordad F; Bronowicki JP; Gordon SC; Zeuzem S; Jacobson IM; Sulkowski MS; Poynard T; Morgan TR; Molony C; Pedicone LD; Sings HL; Burroughs MH; Sniukiene V; Boparai N; Goteti VS; Brass CA; Albrecht JK; Bacon BR;
Gastroenterology; 2012 Sep; 143(3):608-618.e5. PubMed ID: 22626609
[TBL] [Abstract][Full Text] [Related]
16. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.
Verna EC; Saxena V; Burton JR; O'Leary JG; Dodge JL; Stravitz RT; Levitsky J; Trotter JF; Everson GT; Brown RS; Terrault NA;
Transplantation; 2015 Aug; 99(8):1644-51. PubMed ID: 25715116
[TBL] [Abstract][Full Text] [Related]
17. A real life boceprevir use in treatment-experienced HCV genotype 1 patients with advanced fibrosis.
Gheorghe L; Iacob S; Simionov I; Caruntu F; Motoc A; Arama V; Preotescu L; Stefan I; Goldis A; Brisc C; Rugina S; Rednic N
J Gastrointestin Liver Dis; 2014 Mar; 23(1):45-50. PubMed ID: 24689096
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
Vierling JM; Davis M; Flamm S; Gordon SC; Lawitz E; Yoshida EM; Galati J; Luketic V; McCone J; Jacobson I; Marcellin P; Muir AJ; Poordad F; Pedicone LD; Albrecht J; Brass C; Howe AY; Colvard LY; Helmond FA; Deng W; Treitel M; Wahl J; Bronowicki JP
J Hepatol; 2014 Apr; 60(4):748-56. PubMed ID: 24362076
[TBL] [Abstract][Full Text] [Related]
19. Phase III results in Genotype 1 naïve patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin.
Kwo PY
Liver Int; 2012 Feb; 32 Suppl 1():39-43. PubMed ID: 22212570
[TBL] [Abstract][Full Text] [Related]
20. Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir.
Sterling RK; Kuo A; Rustgi VK; Sulkowski MS; Stewart TG; Fenkel JM; El-Genaidi H; Mah'moud MA; Abraham GM; Stewart PW; Akushevich L; Nelson DR; Fried MW; Di Bisceglie AM
Aliment Pharmacol Ther; 2015 Apr; 41(7):671-85. PubMed ID: 25627020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]